Phase I dose-escalation study of oral SKI-606 [bosutinib] in subjects with advanced malignant solid tumors
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2013
At a glance
- Drugs Bosutinib (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 21 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Nov 2009 Planned end date changed from 1 Jun 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
- 03 Nov 2009 Planned number of patients changed from 150 to 151 as reported by ClinicalTrials.gov.